Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) major shareholder William Scully purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average price of $8.79 per share, for a total transaction of $439,500.00. Following the transaction, the insider owned 800,000 shares of the company’s stock, valued at $7,032,000. This trade represents a 6.67% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Prothena Stock Performance
Shares of Prothena stock opened at $9.45 on Friday. The firm has a 50-day simple moving average of $8.98 and a two-hundred day simple moving average of $9.37. Prothena Corporation plc has a fifty-two week low of $7.73 and a fifty-two week high of $11.80. The company has a market cap of $494.71 million, a P/E ratio of -11.25, a price-to-earnings-growth ratio of 3.33 and a beta of -0.30.
Prothena (NASDAQ:PRTA – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.42 million. Prothena had a negative return on equity of 16.45% and a negative net margin of 80.68%. Equities research analysts forecast that Prothena Corporation plc will post 0.08 EPS for the current year.
Hedge Funds Weigh In On Prothena
Analyst Ratings Changes
Several brokerages have recently weighed in on PRTA. UBS Group reaffirmed a “buy” rating on shares of Prothena in a research note on Friday, July 24th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Prothena in a research note on Friday, July 24th. Citigroup reissued an “outperform” rating on shares of Prothena in a report on Friday, May 8th. Weiss Ratings cut shares of Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Finally, Citizens Jmp increased their price objective on shares of Prothena from $19.00 to $20.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.75.
Check Out Our Latest Stock Analysis on PRTA
About Prothena
Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.
The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.
Read More
- Five stocks we like better than Prothena
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
